Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Nuclear Medicine and Molecular Imaging

23.02.2024 | Case Report

68Ga-DOATATOC Brain PET/CT Imaging in a case of Dural Metastasis from Synovial Sarcoma

verfasst von: Shin Ae Han, Jeongryul Ryu, Sang Woo Song, Jae-Seung Kim, Jin-Sook Ryu, Minyoung Oh

Erschienen in: Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Abstract

We present the case of a 70-year-old male patient who underwent a gallium-68 (68Ga)-DOTATOC brain positron emission tomography (PET)/computed tomography (CT) for the assessment of a tumorous lesion on the dura. The patient had previously undergone below-knee amputation due to a mass of synovial sarcoma on the left foot and completed adjuvant chemotherapy approximately 3 months ago. Subsequently, a well-demarcated papillary solid mass located on the dura was surgically excised. Pathological examination confirmed that the dural metastasis originated from synovial sarcoma and post-operative magnetic resonance imaging (MRI) revealed no residual tumor. We conducted a 68Ga-DOTATOC brain PET/CT suspecting a meningioma given the presence of a dural mass. The result showed lower uptake (maximum standardized uptake [SUVmax 4.9]) than the pituitary gland (SUVmax 9.3). Thus, we successfully conducted a differential diagnosis of metastasis from the preexisting malignancy rather than the meningioma. 68Ga-DOTATOC PET/CT is a valuable tool for the differential diagnosis of meningioma. However, metastasis should also be considered, especially in patients with a history of malignancy and lesions showing mild 68Ga-DOTATOC uptake.
Literatur
1.
Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8:311–31.PubMedPubMedCentral
2.
Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–4.CrossRefPubMed
3.
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.CrossRefPubMed
4.
Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:72–82.CrossRefPubMed
5.
Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053–6.PubMed
6.
Hanscheid H, Sweeney RA, Flentje M, Buck AK, Lohr M, Samnick S, et al. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging. 2012;39:1284–8.CrossRefPubMed
7.
Parghane RV, Talole S, Basu S. Prevalence of hitherto unknown brain meningioma detected on (68)Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of (177)Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. World J Nucl Med. 2019;18:160–70.CrossRefPubMedPubMedCentral
8.
Kuyumcu S, Ozkan ZG, Sanli Y, Yilmaz E, Mudun A, Adalet I, Unal S. Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med. 2013;27:538–45.CrossRefPubMed
9.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:2150–1.CrossRefPubMed
10.
Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54:61–7.PubMed
11.
Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 2020;25:4012.CrossRefPubMedPubMedCentral
12.
Wu W, Zhou Y, Wang Y, Liu L, Lou J, Deng Y, et al. Clinical significance of somatostatin receptor (SSTR) 2 in meningioma. Front Oncol. 2020;10:1633.CrossRefPubMedPubMedCentral
13.
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.CrossRefPubMed
14.
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16.CrossRefPubMed
15.
Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.CrossRefPubMed
16.
Albano D, Treglia G, Dondi F, Bertagna F. Prevalence of Brain Incidental lesions detected by (68)Ga-DOTA peptides PET/CT. Med (Kaunas). 2022;58.
17.
Ozguven S, Filizoglu N, Kesim S, Oksuzoglu K, Sen F, Ones T, et al. Physiological biodistribution of (68)Ga-DOTA-TATE in normal subjects. Mol Imaging Radionucl Ther. 2021;30:39–46.CrossRefPubMedPubMedCentral
18.
Filippi L, Palumbo I, Bagni O, Schillaci O, Aristei C, Palumbo B. Somatostatin receptor targeted PET-imaging for diagnosis, radiotherapy planning and theranostics of meningiomas: a systematic review of the literature. Diagnostics (Basel). 2022;12:1666.CrossRefPubMed
19.
Purandare NC, Puranik A, Shah S, Agrawal A, Gupta T, Moiyadi A, et al. Differentiating dural metastases from meningioma: role of 68Ga DOTA-NOC PET/CT. Nucl Med Commun. 2020;41:356–62.CrossRefPubMed
20.
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383–91.CrossRefPubMed
21.
Golemi A, Ambrosini A, Cecchi P, Ruiu A, Chondrogiannis S, Farsad M, Rubello D. (68)Ga-DOTANOC PET/CT detection of multiple extracranial localizations in a patient with anaplastic meningioma. Rev Esp Med Nucl Imagen Mol. 2015;34:258–60.PubMed
22.
Klingenstein A, Haug AR, Miller C, Hintschich C. Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway. Orbit. 2015;34:16–22.CrossRefPubMed
23.
Al Feghali KA, Yeboa DN, Chasen B, Gule MK, Johnson JM, Chung C. The use of (68)Ga-DOTATATE PET/CT in the non-invasive diagnosis of optic nerve sheath meningioma: a case report. Front Oncol. 2018;8:454.CrossRefPubMedPubMedCentral
24.
Florio T, Montella L, Corsaro A, De Chiara A, Apice G, Fazioli F, et al. In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Res. 2003;23:2465–71.PubMed
25.
Ferrari S, Dondi M, Fanti S, Zoboli S, Giacomini S, Mercuri M, Bacci G. Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma. Cancer Biother Radiopharm. 2003;18:847–51.PubMed
26.
Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999;86:1621–7.CrossRefPubMed
27.
Kumar A, Jindal T, Dutta R, Kumar R. Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan. Ann Nucl Med. 2009;23:745–51.CrossRefPubMed
Metadaten
Titel
68Ga-DOATATOC Brain PET/CT Imaging in a case of Dural Metastasis from Synovial Sarcoma
verfasst von
Shin Ae Han
Jeongryul Ryu
Sang Woo Song
Jae-Seung Kim
Jin-Sook Ryu
Minyoung Oh
Publikationsdatum
23.02.2024
Verlag
Springer Nature Singapore
Erschienen in
Nuclear Medicine and Molecular Imaging
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-024-00854-5